Diamyd Medical (STO:DMYD B) Second Quarter 2025 Results
Key Financial Results
- Net loss: kr44.9m (loss widened by 53% from 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Diamyd Medical Earnings Insights
Looking ahead, revenue is forecast to grow 116% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are down 2.5% from a week ago.
Risk Analysis
We should say that we've discovered 6 warning signs for Diamyd Medical (3 shouldn't be ignored!) that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:DMYD B
Diamyd Medical
Develops precision medicine therapies for the treatment of autoimmune diabetes.
Medium-low with adequate balance sheet.
Market Insights
Community Narratives
